The absence of genotoxicity of a mixture of aloin A and B and a commercial aloe gel beverage. (13th June 2022)

• Record Type: Journal Article
• Authors: Hayes, A. Wallace; Clemens, Roger A.; Pressman, Peter
• Is Part Of: Toxicology mechanisms and methods. Volume 32:Number 5(2022)
• Page Start: 385
• Page End: 394
• Publication Date: 2022-06-13
• Subjects: Ames -- microcucleus -- aloin -- aloe -- hydroxyanthracene; Analytical toxicology -- Periodicals; Toxicology -- Periodicals; Toxicology -- Methodology -- Periodicals; 615.907
• DOI: 10.1080/15376516.2021.2023828
• Languages: English
• ISSNs: 1537-6516

Abstract

Abstract: Aloe products are increasingly valued as ingredients in food supplements and as flavoring agents. The global Aloe vera market is varied, large, growing, and increasingly important in food, cosmetics, and medicines. Aloin, an anthraquinone glycoside, is one of the major components by weight of the anthraquinone derivatives of Aloe vera gel. Principal metabolites, aloe emodin and emodin, are a source of debate concerning toxic vs salutary effects, hence the accurate toxicological characterization of these compounds has become increasingly important. The purpose of this study was to determine the genotoxic profile of a stabilized Aloe vera juice product derived from the inner filet and marketed as a beverage currently sold in the European Union containing 8 to 10 ppm aloin and a mixture of purified aloin A and B. The present data confirm that a commercial stabilized Aloe vera gel intended for consumption as a juice beverage is not genotoxic. Furthermore, both aloin A and B were negative in the same assays and therefore are also not genotoxic. These results are consistent with the work of other groups and contrast with data obtained using products containing the Aloe vera latex hydroxyanthracene derivatives (HADs).